Click amount to donate direct to CounterPunch
  • $25
  • $50
  • $100
  • $500
  • $other
  • use PayPal
Please Support CounterPunch’s Annual Fund Drive
We don’t run corporate ads. We don’t shake our readers down for money every month or every quarter like some other sites out there. We only ask you once a year, but when we ask we mean it. So, please, help as much as you can. We provide our site for free to all, but the bandwidth we pay to do so doesn’t come cheap. All contributions are tax-deductible.
FacebookTwitterGoogle+RedditEmail

Selling One Pill to Treat Side Effects of Another Pill

Nearly one in four US women is on antidepressants. The drugs, like Prozac, Paxil and Zoloft, may be happy pills but they are not happy-in-the-bedroom pills. Both older and newer antidepressants cause severe sexual dysfunction like diminished libido and anorgasmia, the inability to achieve orgasm, even with adequate stimulation.

Antidepressant sexual dysfunction is so common, it is used as a sales pitch by the drug manufacturers. “Wellbutrin X works for my depression with a low risk of weight gain and sexual side effects,” say glossy magazine ads showing young men whose sexuality is intact thanks to a better antidepressant. “Can your medicine do all that?” One study found 96 percent patients on a particular antidepressant developed anorgasmia. Who likes those statistics?

Now, marketers of two new sex drugs for women are acknowledging how many women are actually on antidepressants. A Dutch company developing the female libido drugs, Lybrido and Lybridos (which are not yet FDA approved or available) believes the drugs may help the antidepressant-related sexual problems, according to an article in the New York Times magazine. Lybrido contains two possible libido enhancers for women, testosterone and sildenafil, the active ingredient in Viagra. But Lybridos contains testosterone and the antidepressant buspirone, a drug already on the market and known to reverse the negative sexual side effects of antidepressants in some cases by modifying changed levels of the neurotransmitter serotonin that cause the sexual dysfunction.

Buspirone is similar to a “female Viagra” drug that almost reached the market a few years ago. Flibanserin, made by the German company Boehringer Ingelheim, was intended to treat “hypoactive sexual desire disorder” in women but rejected by the FDA. Flibanserin was similar to the antidepressant Serzone which is linked to hyper sexual arousal and the abnormal and painful erectile state known as priapism. Serzone has been withdrawn from markets.

Like Viagra (which had been intended to be an angina drug until its erectile effects appeared) flibanserin, the drug rejected three years ago, was groomed to be an antidepressant drug until its effect on female sexual desire surfaced. Some trial participants did not want to surrender their unused pills at the end of the study. But, despite medical and media excitement about flibanserin and pleas from Big Pharma, Wall Street, husbands, boyfriends and women, the FDA rejected flibanserin in 2010–not for its side effects like dizziness, nausea and sleepiness but because it didn’t seem to work.

Thanks to Big Pharma marketing, Americans increasingly seek a quick fix for “depression,” “sexual dysfunction” and other lifestyle problems. Before direct to consumer marketing of antidepressants, people did not expect to be deliriously happy for no reason or term their problems with marriages and relationships, jobs, health and money, “depression.” Medicalizing lifestyle problems is a cash cow for Big Pharma because advertising works.

Of course, there is no assurance that Lybrido and Lybridos will be approved by the FDA or gain acceptance among doctors and women. But if they do, Big Pharma’s audacious business model of selling one expensive pill to treat side effects of another expensive pill will surely please Wall Street.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

October 15, 2018
Rob Urie
Climate Crisis is Upon Us
Conn Hallinan
Syria’s Chessboard
Patrick Cockburn
The Saudi Atrocities in Yemen are a Worse Story Than the Disappearance of Jamal Khashoggi
Sheldon Richman
Trump’s Middle East Delusions Persist
Justin T. McPhee
Uberrima Fides? Witness K, East Timor and the Economy of Espionage
Tom Gill
Spain’s Left Turn?
Jeff Cohen
Few Democrats Offer Alternatives to War-Weary Voters
Dean Baker
Corporate Debt Scares
Gary Leupp
The Khashoggi Affair and and the Anti-Iran Axis
Russell Mokhiber
Sarah Chayes Calls on West Virginians to Write In No More Manchins
Clark T. Scott
Acclimated Behaviorisms
Kary Love
Evolution of Religion
Colin Todhunter
From GM Potatoes to Glyphosate: Regulatory Delinquency and Toxic Agriculture
Binoy Kampmark
Evacuating Nauru: Médecins Sans Frontières and Australia’s Refugee Dilemma
Marvin Kitman
The Kitman Plan for Peace in the Middle East: Two Proposals
Weekend Edition
October 12, 2018
Friday - Sunday
Becky Grant
My History with Alexander Cockburn and The Financial Future of CounterPunch
Paul Street
For Popular Sovereignty, Beyond Absurdity
Nick Pemberton
The Colonial Pantsuit: What We Didn’t Want to Know About Africa
Jeffrey St. Clair
The Summer of No Return
Jeff Halper
Choices Made: From Zionist Settler Colonialism to Decolonization
Gary Leupp
The Khashoggi Incident: Trump’s Special Relationship With the Saudi Monarchy
Andrew Levine
Democrats: Boost, Knock, Enthuse
Barbara Kantz
The Deportation Crisis: Report From Long Island
Doug Johnson
Nate Silver and 538’s Measurable 3.5% Democratic Bias and the 2018 House Race
Gwen Carr
This Stops Today: Seeking Justice for My Son Eric Garner
Robert Hunziker
Peak Carbon Emissions By 2020, or Else!
Arshad Khan
Is There Hope on a World Warming at 1.5 Degrees Celsius?
David Rosen
Packing the Supreme Court in the 21stCentury
Brian Cloughley
Trump’s Threats of Death and Destruction
Joel A. Harrison
The Case for a Non-Profit Single-Payer Healthcare System
Ramzy Baroud
That Single Line of Blood: Nassir al-Mosabeh and Mohammed al-Durrah
Zhivko Illeieff
Addiction and Microtargeting: How “Social” Networks Expose us to Manipulation
ADRIAN KUZMINSKI
What is Truth?
Michael Doliner
Were the Constitution and the Bill of Rights a Mistake?
Victor Grossman
Cassandra Calls
Ralph E. Shaffer
Could Kavanaugh’s Confirmation Hearing Ended Differently?
Vanessa Cid
Our Everyday Family Separations
Walaa Al Ghussein
The Risks of Being a Journalist in Gaza
Ron Jacobs
Betrayal and Treachery—The Extremism of Moderates
James Munson
Identity Politics and the Ruling Class
P. Sainath
The Floods of Kerala: the Bank That Went Under…Almost
Ariel Dorfman
How We Roasted Donald Duck, Disney’s Agent of Imperialism
Joe Emersberger
Ecuadorian President Lenin Moreno’s Assault on Human Rights and Judicial Independence
Ed Meek
White Victimhood: Brett Kavanaugh and the New GOP Brand
Andrew McLean, MD
A Call for “Open Space”
FacebookTwitterGoogle+RedditEmail